 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
5 March 2002 | Volume 136 Issue 5 | Pages 349-357
Background: Randomized clinical trials have demonstrated the efficacy of adjuvant 5-fluorouracil (5-FU)-based chemotherapy after surgical resection of node-positive colon cancer. Although this treatment became the standard in 1990 following a National Institutes of Health Consensus Conference, among those at least 65 years of age it is less likely to be offered to older or nonwhite patients.
Objective: To determine the association between 5-fu–based chemotherapy and survival in older patients.
Design: Retrospective cohort study.
Setting: Combined database of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and Medicare.
Patients: 4768 patients 65 years of age or older who received a diagnosis of node-positive colon cancer from 1992 to 1996, were covered by Medicare Parts A and B, and resided in the population covered by the SEER program.
Measurements: Propensity scores to control for known predictors of receiving treatment, Cox proportional-hazards models to assess the association of 5-FU therapy with survival, and sensitivity analyses to estimate the possible effects of unknown confounders.
Results: Fifty-two percent of patients received 5-FU therapy. For this sample, the hazard ratio for death associated with 5-FU therapy was 0.66 (95% CI, 0.60 to 0.73). Confounding could have accounted for this association only if an unmeasured confounder were extremely unequally distributed between the treated and untreated groups or increased mortality by at least 50%.
Conclusions: 5-Fluorouracil adjuvant therapy is significantly associated with reduced mortality in older patients, similar to the association found in randomized, controlled trials among younger patients. More frequent use of 5-FU therapy in older patients would probably reduce death from colon cancer.
Editors' Notes
Context
Contribution
Implications
—The Editors
Author and Article Information
From Joseph L. Mailman School of Public Health, the Herbert Irving Comprehensive Cancer Center, and College of Physicians and Surgeons, Columbia University, New York, New York.
Disclaimer: Although this study used the linked seer–medicare database, the interpretation and reporting of these data are solely the authors' responsibility.
Acknowledgments: The authors acknowledge the efforts of the Applied Research Branch, Division of Cancer Prevention and Population Science, National Cancer Institute; the Office of Information Services and the Office of Strategic Planning, Health Care Financing Administration; Information Management Services, Inc; and the SEER Program tumor registries in the creation of the seer–medicare database.
Grant Support: By a grant from the American Cancer Society (RSGHP-01-024-01-CCE). Dr. Grann is the recipient of an American Cancer Society Award (CRTG-98-260-01). Dr. Mitra was supported by a predoctoral fellowship from the National Cancer Institute (T32 CA09529). Dr. Neugut is the recipient of a K05 award from the National Cancer Institute (CA89155). Drs. Heitjan and Neugut were supported in part by NCI P30 CA13696.
Requests for Single Reprints: Alfred I. Neugut, MD, PhD, Division of Medical Oncology, New York Presbyterian Hospital, PH 18-127, 630 West 168th Street, New York, NY 10032; e-mail, ain1{at}columbia.edu.
Current Author Addresses: Dr. Sundararajan: Department of Epidemiology and Preventive Medicine, 553 Kilda Street, Alfred Hospital, Monash Medical School, Melbourne, Victoria 3181, Australia.
Drs. Mitra and Heitjan: Department of Biostatistics, Joseph L. Mailman School of Public Health, Columbia University, 600 West 168th Street, New York, NY 10032.
Dr. Jacobson: Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, 600 West 168th Street, New York, NY 10032.
Drs. Grann and Neugut: Division of Medical Oncology, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032.
Author Contributions: Conception and design: V. Sundararajan, J.S. Jacobson, V.R. Grann, A.I. Neugut.
Analysis and interpretation of the data: V. Sundararajan, N. Mitra, V.R. Grann, D.F. Heitjan, A.I. Neugut.
Drafting of the article: V. Sundararajan, N. Mitra, V.R. Grann, A.I. Neugut.
Critical revision of the article for important intellectual content: V. Sundararajan, N. Mitra, J.S. Jacobson, V.R. Grann, D.F. Heitjan, A.I. Neugut.
Final approval of the article: V. Sundararajan, N. Mitra, J.S. Jacobson, V.R. Grann, D.F. Heitjan, A.I. Neugut.
Provision of study materials or patients: A.I. Neugut.
Statistical expertise: N. Mitra, D.F. Heitjan.
Obtaining of funding: V. Sundararajan, A.I. Neugut.
Collection and assembly of data: V. Sundararajan. ARTICLE
Survival Associated with 5-Fluorouracil–Based Adjuvant Chemotherapy among Elderly Patients with Node-Positive Colon Cancer
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro Treatment of the elderly colorectal cancer patient: SIOG expert recommendations Ann. Onc., October 15, 2008; (2008) mdn532v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Keating, M. B. Landrum, C. N. Klabunde, R. H. Fletcher, S. O. Rogers, W. R. Doucette, D. Tisnado, S. Clauser, and K. L. Kahn Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity? J. Clin. Oncol., May 20, 2008; 26(15): 2532 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Kohne, G. Folprecht, R. M. Goldberg, E. Mitry, and P. Rougier Chemotherapy in Elderly Patients with Colorectal Cancer Oncologist, April 1, 2008; 13(4): 390 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Folprecht, M. T. Seymour, L. Saltz, J.-Y. Douillard, H. Hecker, R. J. Stephens, T. S. Maughan, E. Van Cutsem, P. Rougier, E. Mitry, et al. Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials J. Clin. Oncol., March 20, 2008; 26(9): 1443 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Morris, C. Platell, and B. Iacopetta Tumor-Infiltrating Lymphocytes and Perforation in Colon Cancer Predict Positive Response to 5-Fluorouracil Chemotherapy Clin. Cancer Res., March 1, 2008; 14(5): 1413 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Muss, L. Biganzoli, D. J. Sargent, and M. Aapro Adjuvant Therapy in the Elderly: Making the Right Decision J. Clin. Oncol., May 10, 2007; 25(14): 1870 - 1875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Sanoff, H. Bleiberg, and R. M. Goldberg Managing Older Patients With Colorectal Cancer J. Clin. Oncol., May 10, 2007; 25(14): 1891 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer Adjuvant Treatment of Colorectal Cancer CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Luo, S. H. Giordano, J. L. Freeman, D. Zhang, and J. S. Goodwin Referral to Medical Oncology: A Crucial Step in the Treatment of Older Patients with Stage III Colon Cancer Oncologist, October 1, 2006; 11(9): 1025 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Elkin, A. Hurria, N. Mitra, D. Schrag, and K. S. Panageas Adjuvant Chemotherapy and Survival in Older Women With Hormone Receptor-Negative Breast Cancer: Assessing Outcome in a Population-Based, Observational Cohort J. Clin. Oncol., June 20, 2006; 24(18): 2757 - 2764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Neugut, M. Matasar, X. Wang, R. McBride, J. S. Jacobson, W.-Y. Tsai, V. R. Grann, and D. L. Hershman Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly J. Clin. Oncol., May 20, 2006; 24(15): 2368 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Viotti, C. Vigliano, B. Lococo, G. Bertocchi, M. Petti, M. G. Alvarez, M. Postan, and A. Armenti Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment: A Nonrandomized Trial Ann Intern Med, May 16, 2006; 144(10): 724 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Dobie, L.-M. Baldwin, J. A. Dominitz, B. Matthews, K. Billingsley, and W. Barlow Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst, May 3, 2006; 98(9): 610 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Unger, C. A. Coltman Jr, J. J. Crowley, L. F. Hutchins, S. Martino, R. B. Livingston, J. S. Macdonald, C. D. Blanke, D. R. Gandara, E. D. Crawford, et al. Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials J. Clin. Oncol., January 1, 2006; 24(1): 141 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Jessup, A. Stewart, F. L. Greene, and B. D. Minsky Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation JAMA, December 7, 2005; 294(21): 2703 - 2711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Edwards, M. L. Brown, P. A. Wingo, H. L. Howe, E. Ward, L. A. G. Ries, D. Schrag, P. M. Jamison, A. Jemal, X. C. Wu, et al. Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment J Natl Cancer Inst, October 5, 2005; 97(19): 1407 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wasil and S. M. Lichtman Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly Oncologist, September 1, 2005; 10(8): 602 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Lamont, J. E. Herndon II, J. C. Weeks, I. C. Henderson, R. Lilenbaum, R. L. Schilsky, N. A. Christakis, and for the Cancer and Leukemia Group B Criterion Validity of Medicare Chemotherapy Claims in Cancer and Leukemia Group B Breast and Lung Cancer Trial Participants J Natl Cancer Inst, July 20, 2005; 97(14): 1080 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. E. P. P. Lemmens, A. H. van Halteren, M. L. G. Janssen-Heijnen, G. Vreugdenhil, O. J. Repelaer van Driel, and J. W. W. Coebergh Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity Ann. Onc., May 1, 2005; 16(5): 767 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Alberts, D. J. Sargent, S. Gill, and C. L. Loprinzi In Reply J. Clin. Oncol., January 20, 2005; 23(3): 654 - 655. [Full Text] [PDF]
|
|
|
|
|
|
G. Folprecht, D. Cunningham, P. Ross, B. Glimelius, F. Di Costanzo, J. Wils, W. Scheithauer, P. Rougier, E. Aranda, H. Hecker, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Ann. Onc., September 1, 2004; 15(9): 1330 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Labianca, R. Fossati, A. Zaniboni, V. Torri, S. Marsoni, D. Nitti, L. Boffi, M. Scatizzi, B. Tardio, N. Mastrodonato, et al. Randomized Trial of Intraportal and/or Systemic Adjuvant Chemotherapy in Patients With Colon Carcinoma J Natl Cancer Inst, May 19, 2004; 96(10): 750 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. McWilliams, A. M. Zaslavsky, E. Meara, and J. Z. Ayanian Impact of Medicare Coverage on Basic Clinical Services for Previously Uninsured Adults JAMA, August 13, 2003; 290(6): 757 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Rijnsoever, H. Elsaleh, D. Joseph, K. McCaul, and B. Iacopetta CpG Island Methylator Phenotype Is an Independent Predictor of Survival Benefit from 5-Fluorouracil in Stage III Colorectal Cancer Clin. Cancer Res., August 1, 2003; 9(8): 2898 - 2903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Z. Ayanian, M. B. Landrum, E. Guadagnoli, and P. Gaccione Specialty of Ambulatory Care Physicians and Mortality among Elderly Patients after Myocardial Infarction N. Engl. J. Med., November 21, 2002; 347(21): 1678 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Iwashyna and E. B. Lamont Effectiveness of Adjuvant Fluorouracil in Clinical Practice: A Population-Based Cohort Study of Elderly Patients With Stage III Colon Cancer J. Clin. Oncol., October 1, 2002; 20(19): 3992 - 3998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Neugut, A. T. Fleischauer, V. Sundararajan, N. Mitra, D. F. Heitjan, J. S. Jacobson, and V. R. Grann Use of Adjuvant Chemotherapy and Radiation Therapy for Rectal Cancer Among the Elderly: A Population-Based Study J. Clin. Oncol., June 1, 2002; 20(11): 2643 - 2650. [Abstract] [Full Text] [PDF]
|
|
Article
